Tags : Review Acceptance


Regeneron Announces FDA Review Acceptance of EYLEA’s sBLA for the

Shots: The sBLA involves results of P-III PANORAMA trial assessing EYLEA treatment from moderate severe-to-severe non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME) The announced PDUFA date for EYLEA by US FDA is 13 May, 2019. PANORAMA six months’ results has been announced in March 2018 with expected one year results in H2’18 EYLEA […]Read More